Clinica chimica acta; international journal of clinical chemistry · 2025
Evaluation of iMS-IP assay for the detection and typing of monoclonal immunoglobulins.
СтатьяОценочное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Yu, You Liangshun, Zhu Li, Yin Xuejiao, Yao Qiumei, Ding Shengnan, Ge Jiaying, Liu Yi, Tong Hongyan, Jin Jie, Meng Haitao, Yang Min
Аннотация
BACKGROUND: Serum and urine protein electrophoresis have long served as the mainstay for monitoring monoclonal protein (M-protein) levels in assessing treatment response for multiple myeloma (MM). Despite limitations in sensitivity and specificity, these methods remain the primary clinical detection techniques.
METHODS: Leftover serum samples previously analyzed by immunofixation electrophoresis (IFE) were tested using the iMS-IP assay. We evaluated the accuracy, sensitivity, and specificity of the iMS-IP assay and preliminarily assessed its potential utility for minimal residual disease (MRD) monitoring in peripheral blood and distinguishing therapeutic monoclonal antibodies (t-mAbs) within a clinical cohort.
RESULTS: The iMS-IP assay demonstrated high concordance with IFE for M-protein detection while exhibiting superior sensitivity. It detected IgM M-proteins at levels as low as 0.01 g/L and identified trace M-proteins in sera from patients clinically diagnosed with non-secretory MM. Furthermore, the mass spectrometry-based method correctly identified therapeutic mAbs in 87.5 % (7/8) of cases, significantly outperforming IFE.
CONCLUSIONS: The iMS-IP assay shows potential to replace IFE and advance M-protein screening, diagnosis, and monitoring. Further validation of its clinical sensitivity and specificity is warranted to explore its feasibility for peripheral blood MRD assessment.
METHODS: Leftover serum samples previously analyzed by immunofixation electrophoresis (IFE) were tested using the iMS-IP assay. We evaluated the accuracy, sensitivity, and specificity of the iMS-IP assay and preliminarily assessed its potential utility for minimal residual disease (MRD) monitoring in peripheral blood and distinguishing therapeutic monoclonal antibodies (t-mAbs) within a clinical cohort.
RESULTS: The iMS-IP assay demonstrated high concordance with IFE for M-protein detection while exhibiting superior sensitivity. It detected IgM M-proteins at levels as low as 0.01 g/L and identified trace M-proteins in sera from patients clinically diagnosed with non-secretory MM. Furthermore, the mass spectrometry-based method correctly identified therapeutic mAbs in 87.5 % (7/8) of cases, significantly outperforming IFE.
CONCLUSIONS: The iMS-IP assay shows potential to replace IFE and advance M-protein screening, diagnosis, and monitoring. Further validation of its clinical sensitivity and specificity is warranted to explore its feasibility for peripheral blood MRD assessment.